Amplifying STING activation by bioinspired nanomedicine for targeted chemo- and immunotherapy of acute myeloid leukemia

Wang, Xiaoqi; Huang, Ruihao; Wu, Wei; Xiong, Jingkang; Wen, Qiye; Zeng, Yunjing; Chen, Ting; Li, Jiali; Zhang, Cheng; Zhong, Jiang; Yang, Shijie; Zhang, Xi

doi:10.1016/j.actbio.2022.11.007

Cited by 16 publications

(14 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…214 Different CM source, including erythrocytes, platelets (PLTs), macrophages, T-cells, natural killer (NKs) cells, DCs, tumor cells, and bacteria, endowing various properties to biomimetic NPs. [215][216][217][218][219][220][221] As illustrated in Figure 2A, Qing et al 222 Interestingly, the natural ligands on the T-CM could act as a decoy to deplete immunosuppressive molecules in the TME, including transforming growth factor β1 (TGF-β1) and PD-L1, thus facilitating the restoration of cytotoxic properties of cytotoxic T lymphocytes (CTL). To fully take advantage of the proteins on the different CMs, various types of CMs can be fused to complement each other.…”

Section: Biomimetic Npsmentioning

confidence: 99%

“…Interestingly, biomimetic designs based on CM coating innovatively combines natural and artificial nanomaterials strengths, endowing NPs with remarkable functions, such as excellent biocompatibility, low immunogenicity, and specific targeting ability 214 . Different CM source, including erythrocytes, platelets (PLTs), macrophages, T‐cells, natural killer (NKs) cells, DCs, tumor cells, and bacteria, endowing various properties to biomimetic NPs 215–221 . As illustrated in Figure 2A, Qing et al 222 fabricated T‐cell‐mimicking NPs which are composed of the T‐CM and dacarbazine‐loaded PLGA NPs to directly kill tumor cells by releasing anticancer drugs and providing FasL.…”

Section: Np Technologiesmentioning

confidence: 99%

See 1 more Smart Citation

Advances and applications of nanoparticles in cancer therapy

Huang,

He,

Liang

et al. 2024

MedComm – Oncology

View full text Add to dashboard Cite

Rapid growth in nanoparticles (NPs) as delivery systems holds vast promise to promote therapeutic approaches for cancer treatment. Presently, a diverse array of NPs with unique properties have been developed to overcome different challenges and to achieve sophisticated delivery routes for enhancement of a series of therapies. Inspiring advances have been achieved in the field of cancer therapy using NPs. In this review, we aim to summarize the up‐to‐date progression of NPs for addressing various challenges, and expect to elicit novel and potential opportunities alternatively. We first introduce different sorts of NP technologies, illustrate their mechanisms, and present their applications. Then, the achievements made by NPs to break obstacles in delivering cargoes to specific sites through particular routes are highlighted, including long‐circulation, tumor targeting, responsive release, and subcellular localization. We subsequently retrospect recent research of NPs in different cancer treatments from single therapy, like chemotherapy, to combination therapy, like chemoradiotherapy, and to integrative therapy. Finally, the challenges and perspectives of NPs in cancer therapy, and their potential impact on the field of oncology are discussed. We believe this review can offer a deeper understanding of the challenges and opportunities of NPs for cancer therapy.

show abstract

Section: Biomimetic Npsmentioning

confidence: 99%

Section: Np Technologiesmentioning

confidence: 99%

Advances and applications of nanoparticles in cancer therapy

Huang,

He,

Liang

et al. 2024

MedComm – Oncology

View full text Add to dashboard Cite

show abstract

“…Wang et al fabricated a leukemia cell membrane-camouflaged HMnO 2 nanocarrier with encapsulated DOX, in which Mn 2þ activated the STING pathway along with DOX-induced dsDNA cleavage and ICD, synergistically eliminating acute myeloid leukemia via combined chemotherapy and immunotherapy. [103] Nevertheless, the combination of these two therapies presents issues of high toxicity, side effects, and ineffectiveness in some patients. [104] Combined with PTT or PDT, the immune response is enhanced, resulting in synergistic effects, reduced toxicity, and tumor-bearing mice.…”

Section: Chemotherapy Combined With Immunotherapymentioning

confidence: 99%

Nanotechnology‐Empowered Combination Cancer Immunotherapies: Mechanisms, Synergies, and Perspectives

Pan,

Xue,

Liang

2024

Advanced NanoBiomed Research

View full text Add to dashboard Cite

This review is aiming to systematically elucidate the unique role of nanotechnology in optimizing therapeutic modalities for combinatorial cancer immunotherapy, which enables the synergistic integration of multiple treatment strategies. In particular, nanotechnology has enabled the synergistic combination of immunotherapy with physical therapies, chemotherapy, metal therapy, and nucleic acid therapy. In each combination regimen, nanocarriers play multifaceted roles by achieving targeted codelivery of different therapeutics and optimizing each individual treatment modality. This offers new paradigms to guide precision medicine in cancer treatment. Immunotherapy alone is unlikely to achieve personalized precision medicine for cancer, and new treatment modalities are needed in the future. To overcome technical bottlenecks and realize precise regulation of the tumor microenvironment for personalized cancer treatment, it is crucial to develop novel nanosystems with integrated sensing, targeting, and therapeutic functionalities.

show abstract

“…Li et alintroduced chitosan-modified hollow MnO 2 nanomaterials as a resveratrol loading system, which indicated that MnO 2 nanomaterials could also serve as a potential central nervous system drug delivery system for the treatment of spinal cord injury (68). Wang et al show that a leukemia cell membrane (LCM)-camouflaged hollow MnO 2 nanocarrier (HM) with encapsulated doxorubicin (DOX) (denoted LHMD) could bind specifically to AML cells with a homologous targeting effect (69). LHMD rationally deliver chemotherapeutic agents and to trigger Mn 2+ mediated STING pathway activation for potent immune and chemotherapy against AML cells.…”

Section: Basic Biological Activity Of Mno 2 Nanomaterialsmentioning

confidence: 99%

“…Wang et al. show that a leukemia cell membrane (LCM)-camouflaged hollow MnO 2 nanocarrier (HM) with encapsulated doxorubicin (DOX) (denoted LHMD) could bind specifically to AML cells with a homologous targeting effect ( 69 ). LHMD rationally deliver chemotherapeutic agents and to trigger Mn 2+ mediated STING pathway activation for potent immune and chemotherapy against AML cells.…”

Section: Medical Application Of Mno 2 Nanomaterialsmentioning

confidence: 99%

Advances of MnO2 nanomaterials as novel agonists for the development of cGAS-STING-mediated therapeutics

Zhang

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

As an essential micronutrient, manganese plays an important role in the physiological process and immune process. In recent decades, cGAS-STING pathway, which can congenitally recognize exogenous and endogenous DNA for activation, has been widely reported to play critical roles in the innate immunity against some important diseases, such as infections and tumor. Manganese ion (Mn2+) has been recently proved to specifically bind with cGAS and activate cGAS-STING pathway as a potential cGAS agonist, however, is significantly restricted by the low stability of Mn2+ for further medical application. As one of the most stable forms of manganese, manganese dioxide (MnO2) nanomaterials have been reported to show multiple promising functions, such as drug delivery, anti-tumor and anti-infection activities. More importantly, MnO2 nanomaterials are also found to be a potential candidate as cGAS agonist by transforming into Mn2+, which indicates their potential for cGAS-STING regulations in different diseased conditions. In this review, we introduced the methods for the preparation of MnO2 nanomaterials as well as their biological activities. Moreover, we emphatically introduced the cGAS-STING pathway and discussed the detailed mechanisms of MnO2 nanomaterials for cGAS activation by converting into Mn2+. And we also discussed the application of MnO2 nanomaterials for disease treatment by regulating cGAS-STING pathway, which might benefit the future development of novel cGAS-STING targeted treatments based on MnO2 nanoplatforms.

show abstract

Amplifying STING activation by bioinspired nanomedicine for targeted chemo- and immunotherapy of acute myeloid leukemia

Cited by 16 publications

References 42 publications

Advances and applications of nanoparticles in cancer therapy

Advances and applications of nanoparticles in cancer therapy

Nanotechnology‐Empowered Combination Cancer Immunotherapies: Mechanisms, Synergies, and Perspectives

Advances of MnO2 nanomaterials as novel agonists for the development of cGAS-STING-mediated therapeutics

Contact Info

Product

Resources

About